CN1252309A - 含有稳定剂的甲型肝炎减毒活疫苗及制备方法 - Google Patents

含有稳定剂的甲型肝炎减毒活疫苗及制备方法 Download PDF

Info

Publication number
CN1252309A
CN1252309A CN98123772A CN98123772A CN1252309A CN 1252309 A CN1252309 A CN 1252309A CN 98123772 A CN98123772 A CN 98123772A CN 98123772 A CN98123772 A CN 98123772A CN 1252309 A CN1252309 A CN 1252309A
Authority
CN
China
Prior art keywords
vaccine
hepatitis
gram
stabilizing agent
attenuated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN98123772A
Other languages
English (en)
Other versions
CN1073858C (zh
Inventor
毛江森
陈念良
柴少爱
张峰
王平
谢汝瑛
高丽美
余哲
黄海鹰
毛子安
吴海光
陈卓
黄伟新
钱汶
刘春江
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PUKANG BIOLOGICAL TECHNOLOGY Co ZHEJIANG PROV ACADEMY OF MEDICAL SCIENCES
Original Assignee
PUKANG BIOLOGICAL TECHNOLOGY Co ZHEJIANG PROV ACADEMY OF MEDICAL SCIENCES
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PUKANG BIOLOGICAL TECHNOLOGY Co ZHEJIANG PROV ACADEMY OF MEDICAL SCIENCES filed Critical PUKANG BIOLOGICAL TECHNOLOGY Co ZHEJIANG PROV ACADEMY OF MEDICAL SCIENCES
Priority to CN98123772A priority Critical patent/CN1073858C/zh
Publication of CN1252309A publication Critical patent/CN1252309A/zh
Application granted granted Critical
Publication of CN1073858C publication Critical patent/CN1073858C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

一种含有稳定剂的甲型肝炎减毒活疫苗及制备方法,其疫苗包含有高浓度的氯化镁和硫酸镁,以及明胶、乳糖组成的甲型肝炎病毒稳定剂。将甲肝病毒浓缩液按每人份接种病毒量比例加入到上述含有甲型肝炎病毒稳定剂的基础氨基酸培养基(MEM)平衡盐溶液中,即制成含有稳定剂的甲肝减毒活疫苗。本发明工艺合理,疫苗安全性和稳定性好,有效期长,预防甲型肝炎效果好,具有重大社会经济效益和实施价值。

Description

含有稳定剂的甲型肝炎减毒活疫苗及制备方法
本发明属于甲型肝炎减毒活疫苗及制备方法，尤其是含有稳定剂的甲型肝炎减毒活疫苗及制备方法，适用于预防人体甲型肝炎的减毒活疫苗及制备的场合。
病毒性肝炎是我国最主要的传染病，而甲型肝炎占已知六种病毒性肝炎发病率的首位。自1992年以来，全国已有近一亿人接种液体剂型的甲型肝炎减毒活疫苗，获得了非常满意的流行病学保护效果。甲肝的年发病率平均每年以20％左右的速度下降。但是，由于我国处于发展中国家，许多边远地区交通仍然不便，而一般的液体剂型甲型肝炎减毒活疫苗在4-8℃条件保存有效期只有3个月。
根据我国国情，为控制甲型肝炎的流行，接种甲型肝炎减毒活疫苗是一种行之有效的方法。因此，须使广大的人群，特别是农村人群都能接种到安全的、高效的甲型肝炎减毒活疫苗。
本发明的目的就在于提供一种安全、高效、稳定性好、有效期长的甲型肝炎减毒活疫苗新剂型-即含有稳定剂的甲型肝炎减毒活疫苗及制备方法。
本发明为含有稳定剂的甲型肝炎减毒活疫苗，疫苗中包含有高浓度的氯化镁和硫酸镁，以及明胶、乳糖组成的甲型肝炎病毒稳定剂。
甲型肝炎病毒稳定剂的组成为：氯化镁，疫苗中终浓度为0.3-0.45克％、硫酸镁，疫苗中终浓度为0.1-0.25克％、明胶，疫苗中终浓度为0.10-0.50克％、乳糖，疫苗中终浓度为3.0-3.5克％。
含有稳定剂的甲型肝炎减毒活疫苗的制备方法，每100毫升去离子蒸馏水中加入可耐高温灭菌的基础氨基酸培养基(MEM)平衡盐0.94克，待溶解后加入明胶0.1-0.50克，将该溶液温热，待明胶充分溶解后再加入乳糖3.0-3.5克，然后加入用去离子蒸馏水溶解好的氯化镁0.3-0.45克和硫酸镁0.1-0.25克。过滤，分装，蒸气高压灭菌。再将甲肝病毒浓缩液按每人份接种病毒量6.5-7.0log10TCID50比例加入到上述含有甲型肝炎减毒活疫苗稳定剂的基础氨基酸培养基(MEM)平衡盐溶液中进行灌装、封口，基础氨基酸培养基(MEM)平衡盐溶液为可耐高温灭菌的基础氨基酸培养基(MEM)平衡盐溶液，基础氨基酸培养基(MEM)平衡盐溶液的PH值为7.0-7.4。
本发明的含有稳定剂的甲型肝炎减毒活疫苗及制备方法，与现有技术相比，工艺合理，安全性和稳定性好，有效期长，通常4-8℃保存有效期可达6个月或以上，预防甲肝效果好，具有重大社全经济效益和实施价值。
本发明的含有稳定剂的甲型肝炎减毒活疫苗及制备方法，其实施方案为：疫苗中包含有高浓度的氯化镁和硫酸镁，以及明胶、乳糖、组成的甲型肝炎病毒稳定剂。
甲型肝炎病毒稳定剂的组成为：氯化镁，疫苗中终浓度为0.3-0.45克％、硫酸镁，疫苗中终浓度为0.1-0.25克％、明胶，疫苗中终浓度为0.10-0.50克％、乳糖，疫苗中终浓度为3.0-3.5克％。
含有稳定剂的甲型肝炎减毒活疫苗的制备方法，每100毫升去离子蒸馏水中加入可耐高温灭菌的基础氨基酸培养基(MEM)平衡盐0.94克，待溶解后加入明胶0.1-0.50克，将该溶液温热，待明胶充分溶解后再加入乳糖3.0-3.5克，然后加入用去离子蒸馏水溶解好的氯化镁0.3-0.45克和硫酸镁0.1-0.25克。过滤，分装，蒸气高压灭菌。再将甲肝病毒浓缩液按每人份接种病毒量比例6.5-7.0log10TCID50加入到上述含有甲型肝炎减毒活疫苗稳定剂的基础氨基酸培养基(MEM)平衡盐溶液中进行过滤、灌封，即制得含有稳定剂的甲型肝炎减毒活疫苗，其中基础氨基酸培养基(MEM)平衡盐溶液为可耐高温灭菌的基础氨基酸培养基(MEM)平衡盐溶液，基础氨基酸培养基(MEM)平衡盐溶液的PH值为7.0-7.4。
用于制备含有稳定剂的甲型肝炎减毒活疫苗是采用经低温减毒的、用组织培养法繁殖的、经纯化的、对人体接种不发生肝炎、也不产生其他反应的甲型活病毒液。
实施例1：
含有稳定剂的甲肝减毒活疫苗4-8℃存放24周，疫苗感染滴度下降0.33log10TCID50/ml，而不含有稳定剂的甲肝减毒活疫苗4-8℃保存24周，疫苗感染性滴度则下降0.76log10TCID50/ml。两者有明显差异。(见表1)
表1.H2株甲肝减毒活疫苗加稳定剂和未加稳定剂保存后滴度比较
批号     4-8℃保存(周)疫苗log10TCID50/ml
原始滴度   6   12   18   21   24   27   32   34
 950509     7.00   6.83   6.83   6.73   6.17   6.17   ND   ND   ND
 950510加稳定剂     7.1   7.17   7.17   7.00   7.00   6.83   6.50   6.00   ND
 950829     6.83   6.13   6.33   6.13   5.88   6.13   6.13   ND   5.0
 950329加稳定剂     7.13   7.0   7.0   7.13   6.83   6.32   6.33   ND   5.33
实施例2：
将加有稳定剂的甲肝减毒活疫苗与未加有稳定剂的甲肝减毒活疫苗进行热稳定性试验，结果证明，分别在25℃和37.0℃条件下保存15天，加有稳定剂的甲肝减毒活疫苗对热的稳定性明显比未加有稳定剂的甲肝减毒活疫苗好。表2.  稳定剂对不同温度保存甲肝减毒活疫苗滴度的影响
疫苗批号   稳定剂   原始滴度     疫苗log10TCID50/ml
     25℃     37℃
  7天   15天     15天
  9501     -   6.50   6.50  6.50     4.00
  9502     -   6.83   6.50  6.17     4.00
  9701-1     +   6.75   6.31  6.31     4.50
  9701-2     +   6.80   6.57  6.57     4.33

Claims (3)

1、含有稳定剂的甲型肝炎减毒活疫苗，其特征是疫苗中包含有高浓度的氯化镁和硫酸镁，以及明胶、乳糖组成的甲型肝炎病毒稳定剂。
2、如权利要求1所述的疫苗，其特征是甲型肝炎病毒稳定剂组成为：氯化镁，疫苗中终浓度为0.3-0.45克％，硫酸镁，疫苗中终浓度为0.1-0.25克％，明胶，疫苗中终浓度为0.1-0.5克％，乳糖，疫苗中终浓度为3.0-3.5克％。
3、根据权利要求1所述的含有稳定剂的甲型肝炎减毒活疫苗的制备方法，其特征是100毫升去离子蒸馏水中加入基础氨基酸培养基(MEM)平衡盐0.94克，待溶解后加入明胶0.1-0.5克、乳糖3.0-3.5克，然后加入事先用去离子蒸馏水溶解好的硫酸镁0.1-0.25和氯化镁0.3-0.45克，再将甲肝病毒浓缩液按每人份接种病毒量6.5-7.0 log10TCID50比例，加入到上述含有甲肝减毒活疫苗稳定剂的基础氨基酸培养基(MEM)平衡盐溶液中进行安瓶灌装、封口，即制得含有稳定剂的甲型肝炎减毒活疫苗。
CN98123772A 1998-10-28 1998-10-28 含有稳定剂的甲型肝炎减毒活疫苗及制备方法 Expired - Lifetime CN1073858C (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN98123772A CN1073858C (zh) 1998-10-28 1998-10-28 含有稳定剂的甲型肝炎减毒活疫苗及制备方法

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN98123772A CN1073858C (zh) 1998-10-28 1998-10-28 含有稳定剂的甲型肝炎减毒活疫苗及制备方法

Publications (2)

Publication Number Publication Date
CN1252309A true CN1252309A (zh) 2000-05-10
CN1073858C CN1073858C (zh) 2001-10-31

Family

ID=5228343

Family Applications (1)

Application Number Title Priority Date Filing Date
CN98123772A Expired - Lifetime CN1073858C (zh) 1998-10-28 1998-10-28 含有稳定剂的甲型肝炎减毒活疫苗及制备方法

Country Status (1)

Country Link
CN (1) CN1073858C (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115836123A (zh) * 2021-01-19 2023-03-21 新田明胶株式会社 病毒稳定剂、病毒稳定剂用明胶水解物以及含病毒的组合物

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115836123A (zh) * 2021-01-19 2023-03-21 新田明胶株式会社 病毒稳定剂、病毒稳定剂用明胶水解物以及含病毒的组合物

Also Published As

Publication number Publication date
CN1073858C (zh) 2001-10-31

Similar Documents

Publication Publication Date Title
US3983229A (en) Vaccines, the process for preparing the same and the applications thereof
US4070454A (en) Vaccines, the process for preparing the same and the applications thereof
RU2194531C2 (ru) Поливалентные ассоциированные коклюшно-дифтерийно-столбнячно (акдс)-полиомиелитные вакцины
Nungester et al. The effect of mucin on infections by bacteria
CN102406925A (zh) 一种鸡传染性鼻炎、鸡毒支原体二联类脂灭活疫苗的制备方法
CN101139390A (zh) 猪γ干扰素及其编码基因与应用
Klipstein et al. Partial purification and properties of Enterobacter cloacae heat-stable enterotoxin
AU777994B2 (en) An aqueous solution formulation of alpha-interferon
CN1073858C (zh) 含有稳定剂的甲型肝炎减毒活疫苗及制备方法
KR900007644B1 (ko) 백일해 균의 배양 방법, 백일해 톡소이드 및 백일해 백신
Tyzzer A study of immunity produced by infection with attenuated culture-strains of Histomonas meleagridis
US3401219A (en) Moraxella bovis infectious bovine keratoconjunctivitis steam-killed bacterin
CN106929480A (zh) 猪繁殖与呼吸综合征病毒株及其应用
CN1073857C (zh) 冷冻干燥甲型肝炎减毒活疫苗及制备方法
US4503036A (en) Process for producing a biochemical vaccine against Salmonella infection
Kesel et al. Deamination of amino acids by the human oral flora; its role in dental caries immunity
CN107174658A (zh) 人用水痘病毒灭活疫苗及其制备方法
US4287179A (en) Immersion vaccine for enteric redmouth
CN1042797C (zh) 抗菌抗病毒口服液
Hatch et al. Immunogenic substances in culture filtrates and lysates of Pasteurella tularensis
Meamber et al. The preparation of pituitary growth hormone free from lactogenic and thyrotropic hormones
US3836648A (en) Treatment of canine distemper with a microbial product derived from the bacterium achromobacter stenohalis
Burans et al. Kinetics of Haemophilus influenzae type B infection in normal and ribosome-immunized mice using intraperitoneal and intracerebral routes of inoculation.
Gresser et al. Inhibition of arboviruses by a constituent of a staphylococcus.
CN1030086C (zh) 禽霍乱蜂胶菌苗的制备方法

Legal Events

Date Code Title Description
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C06 Publication
PB01 Publication
C53 Correction of patent for invention or patent application
CB02 Change of applicant information

Applicant after: Zhejiang Pukanjg Biotechnology Co., Ltd.

Applicant before: Pukang Biological Technology Co., Zhejiang Prov. Academy of Medical Sciences

COR Change of bibliographic data

Free format text: CORRECT: APPLICANT; FROM: PUKANG BIOLOGICAL TECHNOLOGY CO., ZHEJIANG PROV. ACADEMY OF MEDICAL SCIENCES TO: ZHEJIANG PUKANG BIOLOGICAL TECHNOLOGY CO., LTD.

C14 Grant of patent or utility model
GR01 Patent grant
CX01 Expiry of patent term

Granted publication date: 20011031

CX01 Expiry of patent term